High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

Interleukin-2 (IL-2) was historically one of the few treatments for adults with stage IV solid tumors that could produce complete responses (CRs) that were often durable for decades without further therapy. The majority of complete responders with metastatic renal cell carcinoma (mRCC) and metastati...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Immunother Cancer
Glavni autori: Dutcher, Janice P, Schwartzentruber, Douglas J, Kaufman, Howard L, Agarwala, Sanjiv S, Tarhini, Ahmad A, Lowder, James N, Atkins, Michael B
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2014
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6889624/
https://ncbi.nlm.nih.gov/pubmed/31546315
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-014-0026-0
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items